Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer

George Sgouros, Robert F. Hobbs, Francis B. Atkins, Douglas Van Nostrand, Paul W. Ladenson, Richard L. Wahl

Research output: Contribution to journalReview article

Abstract

Radioiodine therapy of thyroid cancer was the first and remains among the most successful radiopharmaceutical (RPT) treatments of cancer although its clinical use is based on imprecise dosimetry. The positron emitting radioiodine, 124I, in combination with positron emission tomography (PET)/CT has made it possible to measure the spatial distribution of radioiodine in tumors and normal organs at high resolution and sensitivity. The CT component of PET/CT has made it simpler to match the activity distribution to the corresponding anatomy. These developments have facilitated patient-specific dosimetry (PSD), utilizing software packages such as three-dimensional radiobiological dosimetry (3D-RD), which can account for individual patient differences in pharmacokinetics and anatomy. We highlight specific examples of such calculations and discuss the potential impact of 124I PET/CT on thyroid cancer therapy.

Original languageEnglish (US)
Pages (from-to)S41-S47
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume38
Issue numberSUPPL. 1
DOIs
StatePublished - May 1 2011

Keywords

  • Positron emission tomography
  • Radioiodine therapy
  • Three-dimensional radiobiological dosimetry
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Three-dimensional radiobiological dosimetry (3D-RD) with <sup>124</sup>I PET for <sup>131</sup>I therapy of thyroid cancer'. Together they form a unique fingerprint.

  • Cite this